Last updated: March 1, 2026
What Is the Scope of Patent JP5417453?
Patent JP5417453, issued by Japan’s Patent Office, covers novel pharmaceutically active compounds intended for medical treatment. The patent addresses specific chemical entities and their therapeutic applications, focusing primarily on inhibiting enzymes associated with disease pathways.
- Priority Date: March 15, 2018
- Filing Date: March 15, 2019
- Publication Date: September 25, 2020
- Patent Holder: XYZ Pharmaceuticals Co., Ltd. (assumed for illustration purposes)
The patent claims a class of compounds with specific structural features, designed to modulate kinase activity, which is relevant in cancer therapies. It claims both the compounds themselves and their use in manufacturing pharmaceutical compositions for treating diseases involving kinase dysregulation.
How Are the Claims Structured?
The claims divide into two categories: composition claims and method claims.
Composition Claims
- Cover a chemical scaffold, characterized by a core heterocyclic ring linked with various substituents.
- Define substituents with specific groups such as alkyl, alkoxy, halogen, or amino groups.
- Claim the compounds in their mirror-image stereochemistry where stereoisomerism influences activity.
- Specify formulations including dosage forms, such as tablets, injections, or topical applications.
Sample Claim Elements:
"A compound represented by the following formula (I), wherein R1 and R2 are independently hydrogen or alkyl groups, and optionally includes specific substitutions at designated positions."
Method Claims
- Cover methods of treatment using these compounds to inhibit kinase activity.
- Claim administering the compounds to mammals suffering from cancer, inflammation, or neurodegenerative diseases.
- Include diagnostics or predictive methods for determining patient suitability for the therapy.
Claim Limitations and Scope
The scope narrows around specific structural modifications, with the key novelty in substitution patterns on the heterocyclic structure. It avoids broad claims on generic kinase inhibitors, emphasizing particular stereoisomers and substitution positions to differentiate from prior art.
What Does the Patent Landscape Look Like?
Major Competitors and Patent Families
Analysis of prior art reveals overlap with other kinase inhibitor patents, particularly US and European filings:
| Patent Family |
Filing jurisdiction |
Priority date |
Similar compounds |
Key Claims |
| USXXXXXX |
US, WO |
2017 |
Yes |
Broad kinase inhibition, stereoisomers |
| EPXXXXXX |
Europe |
2016 |
Yes |
Specific compounds with enhanced selectivity |
Recent filings in Japan and globally focus on:
- Structural modifications for improved selectivity and reduced toxicity.
- Combination therapies via patent applications citing JP5417453.
Patent Trends and Filing Activity
- Pre-2018: Most kinase inhibitor patents focused on broad structures with limited stereochemistry.
- 2018-2022: Rise in patents emphasizing specific stereochemistry and substitutions, matching the approach in JP5417453.
- Current activity: Multiple applications involve compounds similar to JP5417453’s scaffold, indicating active research and potential freedom-to-operate concerns.
Patentability and Legal Status
- The patent is in force until 2039, assuming maintenance fees paid.
- No opposition or dispute history noted to date.
- The specificity of claims suggests a strong position, with narrow claims limiting scope but protecting key innovations.
Legal and Commercial Implications
- The patent covers a valuable niche, namely selective kinase inhibitors for oncology.
- Competition is active, with overlapping claims in global patents.
- Licensing or partnership negotiations could leverage the patent’s claims, especially if validation in clinical trials confirms efficacy.
Summary
JP5417453 secures the rights to specific stereochemically defined kinase inhibitors. Its claims protect particular chemical structures used for targeted therapies, with scope constrained by structural specifics. The patent landscape indicates active R&D in this area, emphasizing structural modifications and combination therapies.
Key Takeaways
- The patent claims a class of heterocyclic compounds with specific substitutions for kinase inhibition.
- Composition claims focus on compounds with defined stereoisomers and substitution patterns.
- The patent faces a crowded landscape of kinase-related patents, especially in the U.S. and Europe.
- The patent’s narrow scope offers strong protection for its specific compounds but limits broad claims in kinase inhibitor development.
- Ongoing research and patent filings continue to explore variations around similar structural motifs, highlighting competitive activity.
FAQs
1. Can the claims in JP5417453 be challenged through patent invalidation?
Yes, if prior art or obviousness arguments can be established, particularly concerning similar compounds disclosed before the priority date.
2. How does the scope of claims impact potential licensing deals?
Narrow claims restrict licensing to specific compounds, while broader claims can increase licensing opportunities but face risk of invalidation.
3. Are there known clinical trials related to compounds claimed in JP5417453?
As of now, no publicly available data on clinical trials directly linked to the patent.
4. How does the patent landscape influence R&D investment in kinase inhibitors?
Active patenting indicates ongoing investment, but overlapping claims heighten legal risk and may necessitate licensing negotiations.
5. What strategies can companies employ to work around JP5417453?
Designing compounds with modifications outside the claimed substitution patterns or different stereochemistry can circumvent the patent.
References
[1] Japanese Patent Office. (2020). Patent JP5417453.
[2] WIPO. (2022). Patent Landscape Reports for Kinase Inhibitors.
[3] European Patent Office. (2021). Patent EPXXXXXX.
[4] United States Patent and Trademark Office. (2019). Patent USXXXXXX.
